High antileukemic efficiency of CD19-CAR NK cells engineered with Sleeping Beauty transposon vectors
Tobias Bexte(Goethe University Frankfurt), Evelyn Ullrich(Goethe University Frankfurt), R Schubert(Goethe University Frankfurt), LM Reindl(Goethe University Frankfurt), Csaba Miskey(German Cancer Research Center), Veronika Gebel(Goethe University Frankfurt), Lacramioara Botezatu(German Cancer Research Center), Eva Rettinger(Goethe University Frankfurt), Zoltán Ivics(German Cancer Research Center), Olaf Penack(European Society for Blood and Marrow Transplantation), Sabrina Prommersberger(Universitätsklinikum Würzburg), Julia Campe(Goethe University Frankfurt), Michael Hudecek(Universitätsklinikum Würzburg), Anjali Cremer(Goethe University Frankfurt), WS Wels(Goethe University Frankfurt), S Mertlitz(Charité - Universitätsmedizin Berlin)
Cited by 0
Related Papers
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for <i>In Vivo</i> Antitumor Activity
|Cancer Immunology Research|2014|517
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models
|JCI Insight|2019|192
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
|Nature Medicine|2016|185
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
|Journal for ImmunoTherapy of Cancer|2020|142
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
|Bone Marrow Transplantation|2019|119